Cargando…
NrCAM is a marker for substrate‐selective activation of ADAM10 in Alzheimer's disease
The metalloprotease ADAM10 is a drug target in Alzheimer's disease, where it cleaves the amyloid precursor protein (APP) and lowers amyloid‐beta. Yet, ADAM10 has additional substrates, which may cause mechanism‐based side effects upon therapeutic ADAM10 activation. However, they may also serve—...
Autores principales: | Brummer, Tobias, Müller, Stephan A, Pan‐Montojo, Francisco, Yoshida, Fumiaki, Fellgiebel, Andreas, Tomita, Taisuke, Endres, Kristina, Lichtenthaler, Stefan F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460357/ https://www.ncbi.nlm.nih.gov/pubmed/30833305 http://dx.doi.org/10.15252/emmm.201809695 |
Ejemplares similares
-
Cataracts and NrCAM
por: Dove, Alan W.
Publicado: (2001) -
Neurofascin induces neurites by heterophilic interactions with axonal
NrCAM while NrCAM requires F11 on the axonal surface to extend
neurites
Publicado: (1996) -
NrCAM modulates sonic hedgehog signalling by controlling smoothened translocation in the cilium
por: Basu, B, et al.
Publicado: (2015) -
CHL1 and NrCAM are Primarily Expressed in Low Grade Pediatric Neuroblastoma
por: Wachowiak, Robin, et al.
Publicado: (2019) -
NrCAM, a neuronal system cell-adhesion molecule, is induced in papillary thyroid carcinomas
por: Górka, B, et al.
Publicado: (2007)